$BGLC
BioNexus Gene Lab Corp Stock $bglc

$bglc Overview Financials Valuation SEC Filings Company Website

2023 Q2 Form 10-Q Financial Statement

#000147793223003193 Filed on May 09, 2023

Income Statement

Concept	2023 Q2	2023 Q1	2022 Q1
Revenue	$2.567M	$2.377M	$3.029M
YoY Change	3.29%	-21.52%	-12.18%
Cost Of Revenue	$2.227M	$2.008M	$2.695M
YoY Change	-0.65%	-25.49%	-5.97%
Gross Profit	$339.7K	$368.9K	$333.5K
YoY Change	39.61%	10.6%	-42.75%
Gross Profit Margin	13.23%	15.52%	11.01%
Selling, General & Admin	$807.1K	$536.9K	$345.2K
YoY Change	85.91%	55.51%	14.0%
% of Gross Profit	237.58%	145.53%	103.51%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization	$20.69K	$20.90K	$22.31K
YoY Change	-8.57%	-6.32%	110.01%
% of Gross Profit	6.09%	5.66%	6.69%
Operating Expenses	$611.9K	$419.5K	$298.9K
YoY Change	60.49%	40.38%	24.28%
Operating Profit	-$272.2K	-$50.63K	$34.69K
YoY Change	97.3%	-245.95%	-89.86%
Interest Expense	-$3.040K	$2.445K	-$3.320K
YoY Change	31.03%	-173.64%	-1.19%
% of Operating Profit			-9.57%
Other Income/Expense, Net
YoY Change
Pretax Income	-$275.2K	-$53.08K	$31.37K
YoY Change	96.2%	-269.22%	-90.74%
Income Tax	-$15.99K	$15.99K	$14.30K
% Of Pretax Income			45.59%
Net Earnings	-$259.3K	-$69.07K	$17.07K
YoY Change	86.97%	-504.7%	-94.96%
Net Earnings / Revenue	-10.1%	-2.91%	0.56%
Basic Earnings Per Share
Diluted Earnings Per Share	-$0.02	$0.00	$99.70
COMMON SHARES
Basic Shares Outstanding	173.7M shares	173.7M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2023 Q2	2023 Q1	2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$297.1K	$406.8K	$606.9K
YoY Change	-39.44%	-32.97%	-28.87%
Cash & Equivalents	$1.759M	$1.973M	$1.844M
Short-Term Investments
Other Short-Term Assets	$1.462M	$1.566M	$1.237M
YoY Change	72.01%	26.58%	-23.68%
Inventory	$1.166M	$899.6K	$1.649M
Prepaid Expenses
Receivables	$2.196M	$2.529M	$3.035M
Other Receivables	$106.5K	$57.17K	$73.30K
Total Short-Term Assets	$5.227M	$5.459M	$6.601M
YoY Change	-9.35%	-17.31%	-12.72%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.397M	$1.482M	$1.665M
YoY Change	-8.92%	-10.99%	-5.62%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$1.231M	$1.195M	$909.6K
YoY Change	18.48%	31.34%	59.13%
Other Assets
YoY Change
Total Long-Term Assets	$2.672M	$2.728M	$2.574M
YoY Change	2.68%	5.96%	10.23%
TOTAL ASSETS
Total Short-Term Assets	$5.227M	$5.459M	$6.601M
Total Long-Term Assets	$2.672M	$2.728M	$2.574M
Total Assets	$7.899M	$8.187M	$9.175M
YoY Change	-5.61%	-10.78%	-7.31%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.823M	$1.494M	$1.875M
YoY Change	28.69%	-20.35%	-36.79%
Accrued Expenses	$16.10K	$16.73K	$16.41K
YoY Change	14.75%	1.95%	-2.26%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due			$21.03K
YoY Change			-7.92%
Total Short-Term Liabilities	$1.876M	$1.563M	$1.985M
YoY Change	24.89%	-21.23%	-34.62%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$13.02K
YoY Change	-100.0%	-100.0%	-55.03%
Other Long-Term Liabilities	$29.66K	$35.68K	$21.49K
YoY Change		66.03%	-46.15%
Total Long-Term Liabilities	$58.71K	$66.35K	$62.65K
YoY Change	31.8%	5.91%	-9.02%
TOTAL LIABILITIES
Total Short-Term Liabilities	$1.876M	$1.563M	$1.985M
Total Long-Term Liabilities	$58.71K	$66.35K	$62.65K
Total Liabilities	$1.935M	$1.630M	$2.047M
YoY Change	25.09%	-20.4%	-34.09%
SHAREHOLDERS EQUITY
Retained Earnings	$828.1K	$1.087M	$1.529M
YoY Change	-40.46%	-28.91%
Common Stock	$10.93M	$10.93M	$10.78M
YoY Change	0.0%	1.39%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$5.964M	$6.557M	$7.128M
YoY Change
Total Liabilities & Shareholders Equity	$7.899M	$8.187M	$9.175M
YoY Change	-5.61%	-10.78%	-7.31%

Cashflow Statement

Concept	2023 Q2	2023 Q1	2022 Q1
OPERATING ACTIVITIES
Net Income	-$259.3K	-$69.07K	$17.07K
YoY Change	86.97%	-504.7%	-94.96%
Depreciation, Depletion And Amortization	$20.69K	$20.90K	$22.31K
YoY Change	-8.57%	-6.32%	110.01%
Cash From Operating Activities	-$22.04K	-$118.3K	-$37.84K
YoY Change	-88.97%	212.63%	-132.78%
INVESTING ACTIVITIES
Capital Expenditures	$14.36K	$102.00	$32.19K
YoY Change	-1213.18%	-99.68%	3888.97%
Acquisitions
YoY Change
Other Investing Activities	$11.29K	-$4.950K	-$164.9K
YoY Change	-105.12%	-97.0%	-44.09%
Cash From Investing Activities	-$3.050K	-$5.056K	-$197.1K
YoY Change	-98.63%	-97.44%	-33.36%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-4.210K	-$1.779K	$0.00
YoY Change	-103.63%		-100.0%
NET CHANGE
Cash From Operating Activities	-22.04K	-$118.3K	-$37.84K
Cash From Investing Activities	-3.050K	-$5.056K	-$197.1K
Cash From Financing Activities	-4.210K	-$1.779K	$0.00
Net Change In Cash	-29.30K	-$145.7K	-$235.0K
YoY Change	-90.41%	-38.01%	24.36%
FREE CASH FLOW
Cash From Operating Activities	-$22.04K	-$118.3K	-$37.84K
Capital Expenditures	$14.36K	$102.00	$32.19K
Free Cash Flow	-$36.40K	-$118.4K	-$70.03K
YoY Change	-81.66%	69.07%	-161.1%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001737523
CY2023Q1	dei	Amendment Flag AmendmentFlag	false
CY2023Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2023Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0
CY2023Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0
CY2023Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	171218152	shares
CY2023Q1	dei	Document Type DocumentType	10-Q
CY2023Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2023Q1	dei	Document Period End Date DocumentPeriodEndDate	2023-03-31
CY2023Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2023Q1	dei	Entity File Number EntityFileNumber	333-229399
CY2023Q1	dei	Entity Registrant Name EntityRegistrantName	BIONEXUS GENE LAB CORP.
CY2023Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	WY
CY2023Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	35-2604830
CY2023Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	Unit 02, Level 10 Tower B, Avenue 3, The Vertical
CY2023Q1	dei	Entity Address Address Line2 EntityAddressAddressLine2	Business Suite II Bangsar South
CY2023Q1	dei	Entity Address Address Line3 EntityAddressAddressLine3	No. 8 Jalan Kerinchi
CY2023Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	Kuala Lumpur
CY2023Q1	dei	Entity Address Country EntityAddressCountry	MY
CY2023Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	59200
CY2023Q1	dei	City Area Code CityAreaCode	60
CY2023Q1	dei	Local Phone Number LocalPhoneNumber	1221-26512
CY2023Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023Q1	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023Q1	dei	Entity Small Business EntitySmallBusiness	true
CY2023Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2023Q1	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2023Q1	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	173718152	shares
CY2023Q1	us-gaap	Customer Advances Current CustomerAdvancesCurrent	15322	usd
CY2022Q4	us-gaap	Customer Advances Current CustomerAdvancesCurrent	23123	usd
CY2022Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	71072	usd
CY2023Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2023Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	173718152	shares
CY2023Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	30000000	shares
CY2023Q1	us-gaap	Revenues Revenues	2377205	usd
CY2023Q1	us-gaap	Cost Of Revenue CostOfRevenue	2008308	usd
CY2023Q1	us-gaap	Gross Profit GrossProfit	368897	usd
CY2023Q1	us-gaap	Other Income OtherIncome	117344	usd
CY2023Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	536872	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-50631	usd
CY2023Q1	us-gaap	Interest Expense InterestExpense	2445	usd
CY2022Q1	us-gaap	Interest Expense InterestExpense	3326	usd
CY2023Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-53076	usd
CY2023Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	15990	usd
CY2022Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	14299	usd
CY2023Q1	bion	Earning Per Share Basic And Diluted EarningPerShareBasicAndDiluted	-0.001
CY2022Q1	bion	Earning Per Share Basic And Diluted EarningPerShareBasicAndDiluted	0.000
CY2023Q1	bion	Weighted Average Number Of Common Shares Outstanding Basic And Diluted WeightedAverageNumberOfCommonSharesOutstandingBasicAndDiluted	173718152	shares
CY2022Q1	bion	Weighted Average Number Of Common Shares Outstanding Basic And Diluted WeightedAverageNumberOfCommonSharesOutstandingBasicAndDiluted	171218152	shares
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	6665013	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-69066	usd
CY2023Q1	bion	Foreign Currency Translation Loss ForeignCurrencyTranslationLoss	-39039	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	6556908	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-69066	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	17066	usd
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	3972	usd
CY2022Q1	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	4341	usd
CY2023Q1	us-gaap	Depreciation Depreciation	20897	usd
CY2022Q1	us-gaap	Depreciation Depreciation	22307	usd
CY2023Q1	bion	Dividend Income DividendIncome	8692	usd
CY2022Q1	bion	Dividend Income DividendIncome	7230	usd
CY2023Q1	us-gaap	Fair Value Assets Measured On Recurring Basis Change In Unrealized Gain Loss FairValueAssetsMeasuredOnRecurringBasisChangeInUnrealizedGainLoss	37399	usd
CY2022Q1	us-gaap	Fair Value Assets Measured On Recurring Basis Change In Unrealized Gain Loss FairValueAssetsMeasuredOnRecurringBasisChangeInUnrealizedGainLoss	-3779	usd
CY2023Q1	us-gaap	Gain Loss On Sale Of Other Investments GainLossOnSaleOfOtherInvestments	4	usd
CY2022Q1	us-gaap	Gain Loss On Sale Of Other Investments GainLossOnSaleOfOtherInvestments	0	usd
CY2023Q1	us-gaap	Adjustments Noncash Items To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities	-90292	usd
CY2022Q1	us-gaap	Adjustments Noncash Items To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities	40263	usd
CY2023Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-78171	usd
CY2022Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	126988	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts And Other Receivables IncreaseDecreaseInAccountsAndOtherReceivables	-335512	usd
CY2022Q1	us-gaap	Increase Decrease In Accounts And Other Receivables IncreaseDecreaseInAccountsAndOtherReceivables	-330316	usd
CY2023Q1	bion	Increase Decrease In Deferred Cost Of Revenue IncreaseDecreaseInDeferredCostOfRevenue	0	usd
CY2022Q1	bion	Increase Decrease In Deferred Cost Of Revenue IncreaseDecreaseInDeferredCostOfRevenue	67606	usd
CY2023Q1	us-gaap	Increase Decrease In Other Accounts Payable IncreaseDecreaseInOtherAccountsPayable	-433061	usd
CY2022Q1	us-gaap	Increase Decrease In Other Accounts Payable IncreaseDecreaseInOtherAccountsPayable	-208629	usd
CY2023Q1	us-gaap	Increase Decrease In Customer Advances IncreaseDecreaseInCustomerAdvances	-7801	usd
CY2022Q1	us-gaap	Increase Decrease In Customer Advances IncreaseDecreaseInCustomerAdvances	-30200	usd
CY2023Q1	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	0	usd
CY2022Q1	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-77276	usd
CY2023Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-4366	usd
CY2022Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-5007	usd
CY2023Q1	us-gaap	Increase Decrease In Income Taxes Receivable IncreaseDecreaseInIncomeTaxesReceivable	-3540	usd
CY2022Q1	us-gaap	Increase Decrease In Income Taxes Receivable IncreaseDecreaseInIncomeTaxesReceivable	27924	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-118297	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-37839	usd
CY2023Q1	us-gaap	Payments To Acquire Other Investments PaymentsToAcquireOtherInvestments	13646	usd
CY2022Q1	us-gaap	Payments To Acquire Other Investments PaymentsToAcquireOtherInvestments	172172	usd
CY2023Q1	us-gaap	Proceeds From Equity Method Investment Dividends Or Distributions Return Of Capital ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital	8692	usd
CY2022Q1	us-gaap	Proceeds From Equity Method Investment Dividends Or Distributions Return Of Capital ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital	7230	usd
CY2023Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	102	usd
CY2022Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	32191	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-5056	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-197133	usd
CY2023Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-22299	usd
CY2022Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-44625	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-145652	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-279597	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	2118864	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	2123919	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1973212	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1844322	usd
CY2023Q1	bion	Fixed Deposits Placed With Financial Institutions FixedDepositsPlacedWithFinancialInstitutions	1566425	usd
CY2022Q1	bion	Fixed Deposits Placed With Financial Institutions FixedDepositsPlacedWithFinancialInstitutions	1237472	usd
CY2023Q1	bion	Cash At Bank CashAtBank	406787	usd
CY2022Q1	bion	Cash At Bank CashAtBank	606850	usd
CY2023Q1	bion	Cash And Cash Equivalents End Of Financial Year CashAndCashEquivalentsEndOfFinancialYear	1973212	usd
CY2022Q1	bion	Cash And Cash Equivalents End Of Financial Year CashAndCashEquivalentsEndOfFinancialYear	1844322	usd
CY2023Q1	us-gaap	Interest Paid Net InterestPaidNet	2445	usd
CY2022Q1	us-gaap	Interest Paid Net InterestPaidNet	3326	usd
CY2023Q1	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	-12438	usd
CY2022Q1	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	-41946	usd
CY2023Q1	us-gaap	Use Of Estimates UseOfEstimates	<p style="font-size:10pt;font-family:times new roman;margin:0px">In preparing these condensed consolidated financial statements, management makes estimates and assumptions that affect the reported amounts of assets and liabilities in the balance sheets and revenues and expenses during the periods reported. Actual results may differ from these estimates.</p>
CY2023Q1	bion	Tax Recoverable TaxRecoverable	-27823	usd
CY2022Q4	bion	Tax Recoverable TaxRecoverable	-31551	usd
CY2023Q1	bion	Year Ended Us Dollor One Myr Exchange Rate YearEndedUsDollorOneMyrExchangeRate	4.4170
CY2022	bion	Year Ended Us Dollor One Myr Exchange Rate YearEndedUsDollorOneMyrExchangeRate	4.3900
CY2023Q1	bion	Three Months Average Us One Myr Exchange Rate ThreeMonthsAverageUsOneMyrExchangeRate	4.3968
CY2022Q1	bion	Three Months Average Us One Myr Exchange Rate ThreeMonthsAverageUsOneMyrExchangeRate	4.1938
CY2023Q1	us-gaap	Short Term Debt Interest Rate Increase ShortTermDebtInterestRateIncrease	0.06	pure
CY2023Q1	us-gaap	Debt Instrument Interest Rate Terms DebtInstrumentInterestRateTerms	The normal trade credit term is generally on 30 days to 90 days term.
CY2023Q1	us-gaap	Taxes Payable Current And Noncurrent TaxesPayableCurrentAndNoncurrent	0	usd
CY2022Q4	us-gaap	Taxes Payable Current And Noncurrent TaxesPayableCurrentAndNoncurrent	0	usd
CY2023Q1	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	30678	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	30866	usd
CY2023Q1	bion	Income Taxs Liability IncomeTaxsLiability	2855	usd
CY2022Q4	bion	Income Taxs Liability IncomeTaxsLiability	-685	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	55730	usd
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	41090	usd
CY2023Q1	bion	Addition Of Right Of Useliabilities AdditionOfRightOfUseliabilities	0	usd
CY2022	bion	Addition Of Right Of Useliabilities AdditionOfRightOfUseliabilities	32281	usd
CY2023Q1	bion	Accumulated Amortization Of Lease AccumulatedAmortizationOfLease	-3954	usd
CY2022	bion	Accumulated Amortization Of Lease AccumulatedAmortizationOfLease	-15534	usd
CY2023Q1	bion	Foreign Translation Differences ForeignTranslationDifferences	-341	usd
CY2022	bion	Foreign Translation Differences ForeignTranslationDifferences	-2106	usd
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	51436	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	55730	usd
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	3972	usd
CY2022Q1	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	4341	usd
CY2023Q1	bion	Operating Cash Flow From Operating Lease OperatingCashFlowFromOperatingLease	-4366	usd
CY2022	bion	Operating Cash Flow From Operating Lease OperatingCashFlowFromOperatingLease	-126686	usd
CY2023Q1	us-gaap	Right Of Use Asset Obtained In Exchange For Finance Lease Liability RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability	51436	usd
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Finance Lease Liability RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability	55730	usd
CY2023Q1	us-gaap	Finite Lived Intangible Asset Useful Life FiniteLivedIntangibleAssetUsefulLife	P3Y9M
CY2022	us-gaap	Finite Lived Intangible Asset Useful Life FiniteLivedIntangibleAssetUsefulLife	P4Y
CY2023Q1	bion	Weighted Average Discount Rate For Operating Lease WeightedAverageDiscountRateForOperatingLease	0.0640	pure
CY2022	bion	Weighted Average Discount Rate For Operating Lease WeightedAverageDiscountRateForOperatingLease	0.0640	pure
CY2023Q1	us-gaap	Operating Lease Expense OperatingLeaseExpense	855	usd
CY2022	us-gaap	Operating Lease Expense OperatingLeaseExpense	4913	usd
CY2023Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	2262705	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	2262603	usd
CY2023Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	611214	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	590317	usd
CY2023Q1	bion	Add Foreign Translation Differences AddForeignTranslationDifferences	-169724	usd
CY2022Q4	bion	Add Foreign Translation Differences AddForeignTranslationDifferences	-133982	usd
CY2023Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1481767	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1511708	usd
CY2023Q1	us-gaap	Depreciation Depreciation	20897	usd
CY2022Q1	us-gaap	Depreciation Depreciation	22307	usd
CY2023Q1	bion	Other Investments Beginning Balance OtherInvestmentsBeginningBalance	1150898	usd
CY2022	bion	Other Investments Beginning Balance OtherInvestmentsBeginningBalance	749027	usd
CY2023Q1	bion	Addition During The Year AdditionDuringTheYear	13646	usd
CY2022	bion	Addition During The Year AdditionDuringTheYear	511706	usd
CY2023Q1	us-gaap	Disposal Group Not Discontinued Operation Gain Loss On Disposal DisposalGroupNotDiscontinuedOperationGainLossOnDisposal	0	usd
CY2022	us-gaap	Disposal Group Not Discontinued Operation Gain Loss On Disposal DisposalGroupNotDiscontinuedOperationGainLossOnDisposal	-1776	usd
CY2023Q1	bion	Fair Value Loss FairValueLoss	37399	usd
CY2022	bion	Fair Value Loss FairValueLoss	-70628	usd
CY2023Q1	bion	Foreign Exchange Translation ForeignExchangeTranslation	-7268	usd
CY2022	bion	Foreign Exchange Translation ForeignExchangeTranslation	-37431	usd
CY2023Q1	bion	Other Investments Ening Balance OtherInvestmentsEningBalance	1194675	usd
CY2022	bion	Other Investments Ening Balance OtherInvestmentsEningBalance	1150898	usd
CY2023Q1	us-gaap	Other Investments OtherInvestments	1194675	usd
CY2022Q4	us-gaap	Other Investments OtherInvestments	1150898	usd
CY2023Q1	bion	Scheduleofmajorsupplierscostofsalestable Textblock ScheduleofmajorsupplierscostofsalestableTextblock	<table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2023</strong></p></td><td style="BORDER-BOTTOM: #000000 1px solid; PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: #000000 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2022</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2023</strong></p></td><td style="BORDER-BOTTOM: #000000 1px solid; PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: #000000 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2022</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2023</strong></p></td><td style="BORDER-BOTTOM: #000000 1px solid; PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: #000000 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2022</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Purchase</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Percentage of purchases</strong></p></td><td/><td/><td style="BORDER-BOTTOM: #000000 1px solid;"/><td class="hdcell" colspan="5" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Accounts payable trade</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="width:9%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Vendor A</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">410,208</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">504,906</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">20.43</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">18.89</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">408,334</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">502,559</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Vendor B</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">314,739</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">333,751</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">15.67</td><td style="vertical-align:bottom;white-space: nowrap;">%</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">12.49</td><td style="vertical-align:bottom;white-space: nowrap;">%</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">313,300</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">332,200</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Vendor C</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;">213,965</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;">449,494</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;">10.65</td><td style="PADDING-BOTTOM: 1px;vertical-align:bottom;white-space: nowrap;">%</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;">16.82</td><td style="PADDING-BOTTOM: 1px;vertical-align:bottom;white-space: nowrap;">%</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;">199,312</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;">178,749</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;vertical-align:bottom;text-align:right;"><strong>938,912</strong></td><td style="PADDING-BOTTOM: 3px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;vertical-align:bottom;text-align:right;"><strong>1,288,151</strong></td><td style="PADDING-BOTTOM: 3px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;vertical-align:bottom;text-align:right;"><strong>46.75</strong></td><td style="PADDING-BOTTOM: 3px;vertical-align:bottom;white-space: nowrap;"><strong>%</strong></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;vertical-align:bottom;text-align:right;"><strong>48.20</strong></td><td style="PADDING-BOTTOM: 3px;vertical-align:bottom;white-space: nowrap;"><strong>%</strong></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;vertical-align:bottom;text-align:right;"><strong>920,946</strong></td><td style="PADDING-BOTTOM: 3px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;vertical-align:bottom;text-align:right;"><strong>1,013,508</strong></td><td style="PADDING-BOTTOM: 3px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table>
CY2023Q1	bion	Concentration Risk Purchase ConcentrationRiskPurchase	938912	usd
CY2022Q1	bion	Concentration Risk Purchase ConcentrationRiskPurchase	1288151	usd
CY2023Q1	bion	Concentration Risk Percentage ConcentrationRiskPercentage	0.4675	pure
CY2022Q1	bion	Concentration Risk Percentage ConcentrationRiskPercentage	0.4820	pure
CY2023Q1	bion	Concentration Of Risk Accounts Payable Trade ConcentrationOfRiskAccountsPayableTrade	920946	usd
CY2022Q1	bion	Concentration Of Risk Accounts Payable Trade ConcentrationOfRiskAccountsPayableTrade	1013508	usd
CY2023Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	173718152	shares
CY2022Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	171218152	shares
CY2023Q1	us-gaap	Revenues Revenues	2377205	usd
CY2023Q1	us-gaap	Cost Of Revenue CostOfRevenue	2008308	usd
CY2023Q1	us-gaap	Gross Profit GrossProfit	368897	usd
CY2023Q1	us-gaap	Other Income OtherIncome	117344	usd
CY2023Q1	us-gaap	Other General And Administrative Expense OtherGeneralAndAdministrativeExpense	536872	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-50631	usd
CY2023Q1	us-gaap	Interest Expense InterestExpense	2445	usd
CY2023Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-53076	usd
CY2023Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	15990	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-69066	usd
CY2022Q1	us-gaap	Revenues Revenues	3028945	usd
CY2022Q1	us-gaap	Cost Of Revenue CostOfRevenue	2672612	usd
CY2022Q1	us-gaap	Gross Profit GrossProfit	356333	usd
CY2022Q1	us-gaap	Other Income OtherIncome	46394	usd
CY2022Q1	us-gaap	Other General And Administrative Expense OtherGeneralAndAdministrativeExpense	368036	usd
CY2022Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	34691	usd
CY2022Q1	us-gaap	Interest Expense InterestExpense	3326	usd
CY2022Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	31365	usd
CY2022Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	14299	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	17066	usd
CY2023Q1	us-gaap	Assets Assets	8186641	usd
CY2022Q4	us-gaap	Assets Assets	8740162	usd
CY2023Q1	us-gaap	Liabilities Liabilities	1629733	usd
CY2022Q4	us-gaap	Liabilities Liabilities	2075149	usd

Files In Submission

Name	View Source	Status
bion-20230331_cal.xml	Edgar Link	unprocessable
bion-20230331_lab.xml	Edgar Link	unprocessable
0001477932-23-003193-index-headers.html	Edgar Link	pending
0001477932-23-003193-index.html	Edgar Link	pending
0001477932-23-003193.txt	Edgar Link	pending
0001477932-23-003193-xbrl.zip	Edgar Link	pending
bion-20230331.xsd	Edgar Link	pending
bion_10q.htm	Edgar Link	pending
bion_ex311.htm	Edgar Link	pending
bion_ex312.htm	Edgar Link	pending
bion_ex321.htm	Edgar Link	pending
bion_ex322.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
bion-20230331_def.xml	Edgar Link	unprocessable
bion-20230331_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
bion_10q_htm.xml	Edgar Link	completed
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$BGLC
BioNexus Gene Lab Corp Stock $bglc

2023 Q2 Form 10-Q Financial Statement

#000147793223003193 Filed on May 09, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BGLC BioNexus Gene Lab Corp Stock $bglc

2023 Q2 Form 10-Q Financial Statement

#000147793223003193 Filed on May 09, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BGLC
BioNexus Gene Lab Corp Stock $bglc